Skip to main content
Neuilly-sur- Seine on Muck Rack

Neuilly-sur- Seine

As seen in: Arthritis Research & Therapy
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neuilly-sur-

Contact Neuilly-sur-, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009-2022: an interim analysis using the French JIR cohort database | Arthritis Research & Therapy | Full Text

|
By Kremlin Bicêtre, CHU Lyon, CHU Pellegrin, Neuilly-sur- Seine
| Arthritis Research & Therapy Verified
Results Up to June 2022, 692 FMF patients, 59 MKD patients, and 49 TRAPS patients were included in the JIR Cohort in France based on clinical diagnoses. The proportion of patients who received canakinumab was 4.8% of FMF patients (n = 33), 47.5% of MKD patient (n = 28), and 14.3% of TRAPS patients (n = 7). Two FMF patients and two MKD patients were excluded from this analysis as they received canakinumab in a clinical trial setting.
Open in Who Shared Issue with article?
See all 1 articles